Engelmann, Jan http://orcid.org/0000-0001-8818-0138
Wagner, Stefanie
Wollschläger, Daniel
Kaaden, Sabine
Schlicht, Konrad F.
Dreimüller, Nadine
Braus, Dieter F.
Müller, Marianne B.
Tüscher, Oliver
Frieling, Helge
Tadić, André
Lieb, Klaus
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (BMBF grant n°: 01 KG 0906)
Article History
Received: 19 August 2018
Accepted: 22 March 2019
First Online: 30 March 2019
Compliance with ethical standards
:
: PD Dr. André Tadic is designated as inventor of the European patent number 12171541.1–2404 ‘Method for predicting response or non-response to a mono-aminergic antidepressant’. He has received in the last five years consultancy fees from Janssen and Novartis. Prof. Dr. Klaus Lieb is designated as inventor of the European patent number 12171541.1-2404 ‘Method for predicting response or non-response to a mono-aminergic antidepressant’. Prof. Dr. Dieter F. Braus has received in the last 5 years fees for unrestricted educational lectures from Lilly, Janssen, Bayer, Lundbeck, Servier, Shire, TAD Pharma. None of the authors (JE, SW, DW, SK, KFS, ND, MM, OT) has relevant financial interests in this manuscript.
: All patients gave their written informed consent to participate in the study after a complete and extensive description. All study components were approved by the local ethical committee of the Landesärztekammer Rheinland-Pfalz [study code no. 837.166.09 (6671)] and are compliant with the Code of Ethics of the World Medical Association (Declaration of Helsinki) in its current version.